JACKSONVILLE, FL., Nov. 17, 2025 (GLOBE NEWSWIRE) — LFTD Partners Inc. (“LFTD Partners” or the “Company”) (OTCQB: LIFD), the corporate parent of leading hemp, wellness and energy products maker Lifted Made (“Lifted”), today reported its financial results for the third quarter ended September 30, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles and all currency is in U.S. dollars. Income Statement – Q3 2025 Compared to Q3 2024:Revenue increased 4% to $9,056,742, up from $8,691,675 Operating income was $1,312,791, up from an operating loss of $140,703 Net income was $634,257, up from a net loss of $194,399 Basic net income per share was $0.04 per share, up from a loss of $0.01 per share Diluted net income per share was $0.04 per share, up from a loss of...

A total of 12,702 hotels or 1,246,240 hotel rooms in operation as of September 30, 2025. Hotel turnover1 increased 17.5% year-over-year to RMB30.6 billion in the third quarter of 2025. Excluding Steigenberger Hotels GmbH and its subsidiaries (“DH”, or “Legacy-DH”), hotel turnover increased 18.4% year-over-year in the third quarter of 2025. Hotel turnover from the Legacy-DH segment increased 7.3% year-over-year in the third quarter of 2025. Revenue increased 8.1% year-over-year to RMB7.0 billion (US$978 million)2 in the third quarter of 2025, surpassing the high-end of the revenue guidance previously announced of a 2% to 6% increase, compared to the third quarter of 2024. Manachised and franchised (“M&F”) revenue increased 27.2% year-over-year to RMB3.3 billion (US$465 million) in the third quarter of 2025, exceeding the M&F...

CALGARY, Alberta, Nov. 17, 2025 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to report its financial and operating results for the three and nine months ended September 30, 2025. Dollar amounts are expressed in United States dollars, with the exception of Canadian dollar unit prices (“C$”) where indicated and otherwise noted. Highlights for the three and nine months ended September 30, 2025.The Corporation’s natural gas and liquefied natural gas (“LNG”) operating netback increased 2% and 3% to $5.34 and $5.30 per Mcf for the three and nine months ended September 30, 2025, respectively, compared to $5.25 and $5.17 per Mcf for the same periods in 2024, respectively. The increase is due to an increase in average...

— Third Quarter Revenues of RMB 1,693.9 million, increase 65.4% year over year — Third Quarter Net Income of RMB 81.7 million, compared to net loss of RMB 40.9 million in the same period of last year BEIJING, Nov. 17, 2025 (GLOBE NEWSWIRE) — Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial HighlightsRevenues were RMB 1,693.9 million, an increase of 65.4% year over year Gross margin was 21.8%, compared with 13.8% in the third quarter of 2024 Net income was RMB 81.7 million, compared with net loss of RMB 40.9 million in the third quarter of 2024 Adjusted net income (non-GAAP)1 was RMB 88.4 million, compared with adjusted...

LEXIBOOK S1 2025-26 REVENUE: €30.4 million vs €24.6 million (+€5.8 million, +23.6%). OPERATING PROFIT DOWN TO €2.3 million (-€130,000 vs H1 24-25) DUE TO A 0.8-POINT DECREASE IN GROSS MARGIN, AN INCREASE IN PERSONNEL EXPENSES (+€1.0 million) AND AN INCREASE IN ROYALTY EXPENSES (+€1.1 million). NET INCOME DOWN 21% TO €1.9 MILLION VS €2.5 MILLION IN 24-25. The Lexibook Group’s first half of 2025-26 shows significant revenue growth despite a decline in net profit, impacted by lower margins and higher operating costs. Sales momentum varies by geographical area and licensed product.Revenue growth: Revenue reached €30.4 million, up 23.6% compared to last year, driven by growth of 10% in France and 38% in Europe outside France. The rest of the world grew by only 3%. Despite the development plans underway, the current political climate...

GEVORKYAN, a.s. will release its selected financial and operating results for the third quarter of 2025 on Wednesday, November 19, 2025, at 8:00 a.m. CET. The company also invites you to an online call with senior management to discuss the results via Zoom at 9:00 a.m. on the same day. To access the event, click on the link: https://us06web.zoom.us/webinar/register/WN_tVRBEm0ISTKeziIok36NfQAbout GEVORKYAN, a.s. GEVORKYAN, a.s. is a leading European company in the field of powder metallurgy, a global supplier to large multinational companies, and one of the most innovative companies in this industry worldwide. For more information, visit www.gevorkyan.sk.Contact information: Financial matters: Andrej Bátovský, andrej.batovsky@gevorkyan.sk Media: Alexandra Hazuchová, marketing@gevorkyan.sk

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025. Management Commentary: “Q3 reflects the continued progress of our strategy to build a diversified and sustainable biopharmaceutical business. We are pleased with the impact of our medical affairs initiatives and the strengthened engagement within the Canadian medical community, which have contributed to consecutive quarters of revenue growth in Canada. We also continued to translate our scientific leadership into tangible value through new IP and global collaborations. Despite short-term margin pressures, we remain confident...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — “This quarter, we delivered strong net earnings that reflected the first full quarter of royalty revenue from the Borborema Gold Project and substantial investment gains across our mining portfolio.”, said Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation. “With recurring cash flow now beginning to support our core cost base, we are in a stronger position to redeploy capital toward growth – reinforcing our ability to deliver sustained shareholder value.” “The announced acquisition of Maritime Resources by New Found Gold marks another pivotal validation of our long-term investment strategy.” Mr. Goodman continued. “We recognized the intrinsic value of Maritime early and supported the company through market cycles. The transaction highlights our ability to identify...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus  Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to advance transplantation programs IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent business highlights. “The results from our Phase 2 BESTOW trial demonstrated tegoprubart’s excellent efficacy and safety, importantly avoiding many of the long-term toxicities commonly seen with current standard-of-care...

–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025– –The Company raised approximately $100 million in an oversubscribed public offering of common stock, which is expected to fund advancement of the BB-301 Oculopharyngeal Muscular Dystrophy (OMPD) registrational program and associated regulatory filing activities– HAYWARD, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma...